rapid-isolation-viable-circulating-tumor-cells-from-patient-blood

Rapid Isolation of Viable Circulating Tumor Cells from Patient Blood Samples

Circulating tumor cells (CTC) are cells that disseminate from a primary tumor throughout the circulatory system and that can ultimately form secondary ...

Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Programmierten Tod-1 (PD-1), einen hemmenden Rezeptor ausgedr&uuml;ckt auf aktivierten T-Zellen, kann antitumor Immunit&auml;t unterdr&uuml;cken. Diese Phase studiere ich suchte, die Sicherheit und Vertr&auml;glichkeit von Anti-PD-1-Blockade bei Patienten mit soliden Tumoren Behandlung-resistentem bestimmen und antitumor-Aktivit&auml;t, Pharmakodynamik und immunologische korreliert vorl&auml;ufig zu bewerten.

Phase I-&uuml;ber Single-Agent anti-programmed Tod-1 (MDX-1106) in feuerfesten soliden Tumoren Studie: Sicherheit, klinische T&auml;tigkeit, Pharmakodynamik und immunologische korreliert.

Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Blockade der programmierten Tod 1 (PD-1), einen hemmenden Rezeptor, ausgedr&uuml;ckt durch T-Zellen, kann immun Widerstand &uuml;berwinden. Wir pr&uuml;ften die antitumor-Aktivit&auml;t und die Sicherheit der BMS-936558, ein Antik&ouml;rper, der spezifisch PD-1 blockiert.

Article	Year
Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 12682253	2003
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 20516446	2010
Clinical chemistry\| PubMed ID: 22344286	2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine\| PubMed ID: 22658127	2012

John D. Powderly

Biography

JoVE Journal Publications

Other Publications